GlobeNewswire by notified

Spryker Partners With Business Intelligence Solution to Enable Data-Driven Decision Making

Share

minubo’s capabilities, specifically designed for ecommerce, will enable businesses to easily work with data across departments in order to maximize profit

BERLIN and NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spryker, a leading platform for B2B and B2C Enterprise Marketplaces, Thing Commerce, and Unified Commerce, is partnering with minubo, which offers all-in-one, ready-to-use business intelligence. The partnership joins together commerce intelligence and composability to offer a simple and scalable way to achieve company wide holistic data transparency.

Developed for ecommerce, minubo’s business intelligence solution puts everything in one place and is accessible across departments to create a new data culture of truly data-driven work. The company's embedded dashboards are fully customizable and easy to use, allowing more people to utilize data in their daily work and enhance performance.

“Spryker’s experience, strong resources, and leadership in the world of ecommerce made them the ideal candidate to partner with on commerce focused business intelligence,” said Andreas Fischer, CEO at minubo. “We share the same mindset to support our customers on their journey to growth and profitability, and with the embedded minubo dashboards into the Spryker frontend, access to data-driven decision making will be even easier to achieve.”

Spryker’s App Composition Platform provides enterprises with the flexibility needed to adjust to a constantly changing market and to accelerate digital growth and transformation. The best-of-breed platform allows enterprises to choose capabilities, such as minubo’s, to differentiate from their competitors and evolve their business as needed.

“Too many business decisions around ecommerce are made in the dark. With easy access to quality data across departments, ecommerce outcomes can be improved," said Manishi Singh, SVP App Composition Platform at Spryker. “That’s why we are delighted to closely partner with minubo, a strong technology partner within our best-in-class partner ecosystem. The plug-and-play integration guarantees quick daily insights and by embedding these insights directly into the frontend, where employees can find the relevant KPIs for the work, Spryker customers will be able to enhance performance and achieve their business goals.”

minubo – Max Your Profit
All-in-one business intelligence specially developed for e-commerce. minubo offers data integration and linking, analysis and reporting. Profit from full transparency at the touch of a button, across all channels. Provide everyone in your team with access to the relevant data – without lengthy training. Enjoy the benefits of a ready-to-use, complete business intelligence solution in minimal time. For fast project set-up, low cost and zero risk, get minubo.

About Spryker
Spryker is the leading composable commerce platform for enterprises with sophisticated business models to enable growth, innovation, and differentiation. Designed specifically for sophisticated transactional business, Spryker’s easy-to-use, headless, API-first model offers a best of breed approach that provides businesses the flexibility to adapt, scale, and quickly go to market while facilitating faster time-to-value throughout their digital transformation journey. As a global platform leader for B2B and B2C Enterprise Marketplaces, Thing Commerce, and Unified Commerce, Spryker has empowered 150+ global enterprise customers worldwide and is trusted by brands such as ALDI, Siemens, Hilti, and Ricoh. Spryker was recognized by Gartner® as a Visionary in the 2022 Magic Quadrant™ for Digital Commerce and was also ranked as a Strong Performer in the The Forrester Wave™: B2B Commerce Solutions, Q2 2022. Spryker is a privately held technology company headquartered in Berlin and New York. Find out more at https://spryker.com

Contact details:
press@spryker.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Tenaris Announces 2024 First Quarter Results25.4.2024 22:30:25 CEST | Press release

The financial and operational information contained in this press release is based on unaudited consolidated condensed interim financial statements presented in U.S. dollars and prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standard Board and adopted by the European Union, or IFRS. Additionally, this press release includes non-IFRS alternative performance measures i.e., EBITDA, Net cash / debt, Free Cash Flow and Operating working capital days. See exhibit I for more details on these alternative performance measures. LUXEMBOURG, April 25, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) (“Tenaris”) today announced its results for the quarter ended March 31, 2024 in comparison with its results for the quarter ended March 31, 2023. Summary of 2024 First Quarter Results (Comparison with fourth and first quarter of 2023) 1Q 20244Q 20231Q 2023Net sales ($ million)3,4423,4151%4,141(17%)Operating

Combined General Meeting of May 16, 202425.4.2024 22:30:00 CEST | Press release

Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on May 16, 2024, at 10:00 a.m. CET at the Company’s new headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France. The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French “Bulletin des Annonces Légales Obligatoires (BALO)” dated April 8, 2024 (No. 2400716). The meeting notice (avis de convocation) will be published in the BALO and in t

Millicom (Tigo) Board of Directors Appoints Marcelo Benitez as CEO25.4.2024 22:30:00 CEST | Press release

Millicom (Tigo) Board of Directors Appoints Marcelo Benitez as CEO Luxembourg, April 25, 2024 – Millicom announced today that its Board of Directors has appointed Marcelo Benitez as CEO of Millicom, effective June 1, 2024. Benitez has had a distinguished career with Millicom, having joined the company in Paraguay nearly 30 years ago and risen through the Company’s ranks to his most recent role as CEO of TIGO Panama. Benitez's selection completes the final phase of a succession planning and selection process, which included a thorough evaluation of internal and external candidates to ensure that the company's next CEO possesses the vision, experience, talent and leadership qualities necessary to deliver on Millicom's strategic plans. "After an extensive evaluation, it is clear to our Board that Marcelo is the right person to lead Millicom into the future”, indicated Mauricio Ramos, Chair of the Board of Directors of the Company. Under Marcelo’s leadership, TIGO Panama completed the succ

Mohawk Industries Reports Q1 Results25.4.2024 22:10:00 CEST | Press release

CALHOUN, Ga., April 25, 2024 (GLOBE NEWSWIRE) -- Mohawk Industries, Inc. (NYSE: MHK) today announced first quarter 2024 net earnings of $105 million and earnings per share (“EPS”) of $1.64; adjusted net earnings were $119 million, and adjusted EPS was $1.86. Net sales for the first quarter of 2024 were $2.7 billion, a decrease of 4.5% as reported and 5.5% on a legacy and constant basis versus the prior year. During the first quarter of 2023, the Company reported net sales of $2.8 billion, net earnings of $80 million and EPS of $1.26; adjusted net earnings were $112 million, and adjusted EPS was $1.75. Commenting on the Company’s first quarter results, Chairman and CEO Jeff Lorberbaum stated, “Though economic headwinds are impacting industry sales, margins and mix, our first quarter results reflected the positive effect of actions we are taking to enhance our performance. Our earnings per share rose year over year as a result of restructuring, productivity initiatives and benefits from

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®25.4.2024 22:05:00 CEST | Press release

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFIDENCE has been recommended for approval for the treatment of moderate to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19. The CHMP’s positive opinion will now be referred to the European Commission (EC), which will decide whether to grant marketing authorization for TOFIDENCE. If a marketing authorization is granted by the EC, TOFIDENCE will be an addition to the existing biosimilars portfolio of three widely p

HiddenA line styled icon from Orion Icon Library.Eye